NeoGenomics Inc (NEO)
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
- Symbol
- NEO
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Market cap
- $2.42B
- 52 week range
- 7.07 - 20.05
Valuation
- Share price
- $18.36 (close of 2026-09-23)
- P/E (TTM)
- -46.81x
- Price to book
- 3.08x
- Price to free cash flow
- -328.53x
- Enterprise value
- $2.72B
- Book value per share
- $6.14
Price performance
| Period | Change |
|---|
| 1 day | -5.41% |
| 5 days | -2.81% |
| 1 month | +8.13% |
| 3 months | +60.07% |
| 6 months | +126.67% |
| Year to date | +56.12% |
| 1 year | +125.83% |
| 3 years | +51.11% |
| 5 years | -63.24% |
| 10 years | +120.41% |
| All time | +4169.77% |
Profitability and growth
- Return on equity
- -12.91%
- Return on invested capital
- -10.46%
- Return on assets
- -7.94%
- Return on capital employed
- -9.11%
- Gross margin
- 43.21%
- Net margin
- -14.85%
- EBITDA margin
- -10.97%
- Revenue growth
- 10.11%
- Net income growth
- -37.22%
- Free cash flow growth
- 36.02%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -0.30%
- Current ratio
- 3.60x
- Net debt to EBITDA
- 22.45x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $727.33M
- Cost of revenue
- $413.04M
- Gross profit
- $314.29M
- EBITDA
- $-79.81M
- Net income
- $-108.03M
- Earnings per share
- $-0.84
- Research and development
- $37.08M
- Shares outstanding
- 128.10M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $727.33M | $314.29M | $-108.03M | $-0.84 |
| 2024-12-31 | $660.57M | $290.10M | $-78.73M | $-0.62 |
| 2023-12-31 | $591.64M | $244.60M | $-87.97M | $-0.70 |
| 2022-12-31 | $509.73M | $187.90M | $-144.25M | $-1.16 |
| 2021-12-31 | $484.33M | $187.06M | $-8.35M | $-0.07 |
| 2020-12-31 | $444.45M | $185.89M | $4.17M | $0.04 |
| 2019-12-31 | $408.83M | $196.84M | $8.01M | $0.08 |
| 2018-12-31 | $276.74M | $127.27M | $2.64M | $0.03 |
| 2017-12-31 | $240.25M | $101.96M | $-396.00K | $-0.00 |
| 2016-12-31 | $231.81M | $98.10M | $-6.14M | $-0.08 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 43.21% | -14.85% | -12.91% | -10.46% |
| 2024-12-31 | 43.92% | -11.92% | -8.72% | -7.90% |
| 2023-12-31 | 41.34% | -14.87% | -9.34% | -8.14% |
| 2022-12-31 | 36.86% | -28.30% | -14.45% | -10.59% |
| 2021-12-31 | 38.62% | -1.72% | -0.75% | -12.85% |
| 2020-12-31 | 41.83% | 0.94% | 0.60% | -1.35% |
| 2019-12-31 | 48.15% | 1.96% | 1.58% | 3.46% |
| 2018-12-31 | 45.99% | 0.95% | 0.82% | 2.10% |
| 2017-12-31 | 42.44% | -0.16% | -0.23% | 1.14% |
| 2016-12-31 | 42.32% | -2.65% | -3.78% | 0.88% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $159.62M | $341.86M |
| 2024-12-31 | $367.01M | $340.33M |
| 2023-12-31 | $342.49M | $538.20M |
| 2022-12-31 | $263.18M | - |
| 2021-12-31 | $316.83M | - |
| 2020-12-31 | $228.71M | - |
| 2019-12-31 | $173.02M | - |
| 2018-12-31 | $9.81M | $92.88M |
| 2017-12-31 | $12.82M | $91.13M |
| 2016-12-31 | $12.53M | $91.95M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-21.78M | $41.32M |
| 2024-12-31 | $-34.04M | $33.41M |
| 2023-12-31 | $-30.70M | $24.63M |
| 2022-12-31 | $-96.88M | $24.67M |
| 2021-12-31 | $-90.86M | $22.46M |
| 2020-12-31 | $-27.64M | $10.21M |
| 2019-12-31 | $3.34M | $10.00M |
| 2018-12-31 | $30.48M | $6.96M |
| 2017-12-31 | $4.35M | $6.44M |
| 2016-12-31 | $13.94M | $5.44M |
Dividend history
- Most recent payment
- 2020-12-17
| Payment date | Dividend per share |
|---|
| 2020-12-17 | $0.40 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-27
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-28 | Jun/2026 | - |
| 2026-04-28 | - | - |
| 2026-02-17 | - | - |
| 2025-10-28 | - | - |
| 2025-07-29 | - | - |
| 2025-04-29 | - | - |
| 2025-02-18 | - | - |
| 2024-11-05 | - | - |
Filings and sources
- Company website
- neogenomics.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV) · Agilent Technologies, Inc. (A) · Waters Corp (WAT) · IDEXX Laboratories Inc (IDXX) · Mettler-Toledo International Inc (MTD) · Quest Diagnostics Inc (DGX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades